ACTA1 and diabetic kidney disease: In in vitro and in vivo studies of diabetic nephropathy, low-molecular-weight fucoidan significantly increased E-cadherin expression and reduced α-SMA, CTGF, and fibronectin expression in both type 1 and type 2 diabetic models.